



---


# Consolidated H1 2023 Report

Selvita Capital Group

# Table of content

<b>01 — Selected financial data . 4</b>	
1.1. Main results achieved in the reporting period	
1.2. Change of the consolidation rules of Ardigem S.A.	
1.3. Impact of Incentive Scheme on 2021-2024 financial results	
<b>02 — Management Board's comments on financial results . 11</b>	
2.1. Consolidated data excluding incentive scheme impact	
2.2. Contracted (Backlog)	
<b>03 — The group's assets and the structure of assets and liabilities . 17</b>	
3.1. Consolidated data	
<b>04 — Current and projected financial condition . 19</b>	
<b>05 — Significant off-balance sheet items . 20</b>	
<b>06 — Significant events in reporting period . 21</b>	
7.1. Significant events in reporting period	
7.2. Post balance sheet significant events	
7.3. Unusual events occurring in the reporting period	
<b>07 — Management board's information on group's activities . 23</b>	
<b>08 — The capital group structure . 30</b>	
<b>09 — Issuer's corporate bodies . 32</b>	
<b>10 — Information on the shareholders holding (directly or indirectly) at least 5% of the total number of votes at the general shareholders' meeting of the company and on shares held by members of the issuer's Management Board and Supervisory Board . 33</b>	
<b>11 — Additional information . 36</b>	







# 01 — Selected financial data

The consolidated financial statements cover the period from January 1, 2023 to June 30, 2023 with comparative period from January 1, 2022 to June 30, 2022.

From 2023, the Group will no longer consolidate the full financial results of Ardigen S.A. despite no changes in the number of shares held in the company. Details in point 1.1.2.

The Company's Management Board stipulates that the discontinuation of the consolidation of Ardigen's results does not affect any of the Company's business goals set out in the Development Strategy of the Selvita Capital Group for 2022-2025, which did not include Ardigen. The Company, in its periodic reports (in the Management Board's reports on activities), in consultation with the Management Board of Ardigen, still will continue to provide up-to-date information on the development and situation of this company due to the possession of a significant block of Ardigen shares.



## 1.1. Main results achieved in the reporting period

### Consolidated financial data

The table below presents the consolidated financial data of the Selvita S.A. Group.

Selected financial data presented in the interim report were converted to Euro as follows:

1. Items relating to the profit and loss statement and the cash flow statement were converted using the exchange rate constituting the arithmetic average of the exchange rates, applicable as of the last day of every month in the given period, based on the information published by the National Bank of Poland (NBP):
  - for the period from 01/01/2023 r. to 30/06/2023 r.: 4.6130 PLN,
  - for the period from 01/04/2023 r. to 30/06/2023 r.: 4.5256 PLN,
  - for the period from 01/01/2022 r. to 30/06/2022 r.: 4.6427 PLN,
  - for the period from 01/04/2022 r. to 30/06/2022 r.: 4.6381 PLN.
  
2. Balance sheet items were converted using the average exchange rate announced by the NBP applicable as at the balance sheet date; which were:
  - as of 30 June 2023: PLN 4.4503,
  - as of 31 December 2022: PLN 4.6899.





TABLE 1.

The Consolidated financial data of the Selvita S.A. Group – concerning the consolidated balance sheet

Selvita S.A. Group Item	Consolidated data in PLN thousand		Consolidated data in EUR thousand	
	30.06.2023	31.12.2022	30.06.2023	31.12.2022
<b>Total assets</b>	<b>572,408</b>	<b>584,911</b>	<b>128,622</b>	<b>124,717</b>
Trade and other receivables	81,745	98,802	18,368	21,067
Investment in subsidiaries not fully consolidated	11,275	-	2,534	-
Cash and other monetary assets	37,353	74,157	8,393	15,812
Other financial assets	2,056	2,018	462	430
<b>Total liabilities</b>	<b>302,921</b>	<b>311,750</b>	<b>68,068</b>	<b>66,473</b>
Long term liabilities	208,524	189,083	46,856	40,317
Short term liabilities	94,396	122,667	21,211	26,156
<b>Equity</b>	<b>269,487</b>	<b>273,161</b>	<b>60,555</b>	<b>58,245</b>
Share capital	14,684	14,684	3,300	3,131



TABLE 2.

The Consolidated financial data of the Selvita S.A. Group – concerning the consolidated balance sheet

Selvita S.A. Group	Consolidated data in PLN thousand				Consolidated data in EUR thousand			
	From 01.01.2023 to 30.06.2023	From 01.01.2022 to 30.06.2022	From 01.04.2023 to 30.06.2023	From 01.04.2022 to 30.06.2022	From 01.01.2023 to 30.06.2023	From 01.01.2022 to 30.06.2022	From 01.04.2023 to 30.06.2023	From 01.04.2022 to 30.06.2022
<b>Revenues from sales</b>	<b>178,129</b>	<b>174,643</b>	<b>87,535</b>	<b>91,428</b>	<b>38,614</b>	<b>37,617</b>	<b>19,342</b>	<b>19,712</b>
Revenues from subsidies	2,779	1,721	1,615	903	602	371	357	195
Other operating revenues	48	50	-9	23	10	11	-2	5
<b>Revenues from operating activities</b>	<b>180,955</b>	<b>176,413</b>	<b>89,142</b>	<b>92,354</b>	<b>39,227</b>	<b>37,998</b>	<b>19,697</b>	<b>19,912</b>
Operating expenses	-171,294	-164,137	-83,755	-85,532	-37,133	-35,354	-18,507	-18,441
Operating expenses (excl. incentive scheme)	-162,737	-141,531	-79,601	-73,901	-35,278	-30,485	-17,589	-15,933
Depreciation	-22,097	-17,443	-11,678	-8,902	-4,790	-3,757	-2,580	-1,919
Depreciation (excl. IFRS 16 impact)	-14,733	-10,712	-7,967	-5,524	-3,194	-2,307	-1,760	-1,191
Incentive program valuation	-8,557	-22,606	-4,154	-11,630	-1,855	-4,869	-918	-2,508
Profit from operating activities / EBIT	9,662	12,276	5,386	6,823	2,094	2,644	1,190	1,471
<b>Profit from operating activities / EBIT (excl. incentive scheme)</b>	<b>18,219</b>	<b>34,882</b>	<b>9,540</b>	<b>18,453</b>	<b>3,949</b>	<b>7,513</b>	<b>2,108</b>	<b>3,979</b>
Profit before income tax	11,087	9,450	8,602	5,539	2,403	2,036	1,901	1,194
Net profit	10,321	10,173	7,875	4,256	2,237	2,191	1,740	918
<b>Net profit (excl. incentive scheme)</b>	<b>18,878</b>	<b>32,779</b>	<b>12,028</b>	<b>15,886</b>	<b>4,092</b>	<b>7,060</b>	<b>2,658</b>	<b>3,425</b>





Selvita S.A. Group	Consolidated data in PLN thousand				Consolidated data in EUR thousand			
	From 01.01.2023 to 30.06.2023	From 01.01.2022 to 30.06.2022	From 01.04.2023 to 30.06.2023	From 01.04.2022 to 30.06.2022	From 01.01.2023 to 30.06.2023	From 01.01.2022 to 30.06.2022	From 01.04.2023 to 30.06.2023	From 01.04.2022 to 30.06.2022
EBITDA	31,759	29,719	17,064	15,725	6,885	6,401	3,771	3,390
EBITDA (excl. incentive scheme)	40,316	52,325	21,218	27,355	8,739	11,270	4,688	5,898
Net cash flows from operating activities, from continuing operations	20,957	21,106	19,468	458	4,543	4,546	4,302	99
Net cash flows from investing activities, from continuing operations	-30,509	-13,414	-17,330	-8,303	-6,614	-2,889	-3,829	-1,790
Net cash flows from financing activities, from continuing operations	-8,324	-20,292	-2,796	-10,271	-1,804	-4,371	-618	-2,214
Total net cash flows, from continuing operations	-34,709	-10,274	-11,640	-16,175	-7,524	-2,213	-2,572	-3,487
Number of shares (weighted average)	18,355,474	18,355,474	18,355,474	18,355,474	18,355,474	18,355,474	18,355,474	18,355,474
Profit (loss) per share (in PLN)	0.56	0.47	0.43	0.20	0.12	0.10	0.09	0.04
Diluted profit (loss) per share (in PLN)	0.56	0.47	0.43	0.20	0.12	0.10	0.09	0.04
Book value per share (in PLN)	14.74	12.62	14.74	12.62	3.31	2.70	3.31	2.70
Diluted book value per share (in PLN)	14.74	12.62	14.74	12.62	3.31	2.70	3.31	2.70
Declared or paid dividend per share (in PLN)	-	-	-	-	-	-	-	-



## 1.2. Change of the consolidation rules of Ardigen S.A.

On January 18, 2023, the Company became aware of the registration of the increase in the share capital of Ryvu Therapeutics S.A. with its registered office in Kraków („Ryvu”), as a result of which the share of Mr. Paweł Przewięźlikowski in the total number of votes at the General Meeting of Ryvu decreased from 33.03% to 27.91%.

Pursuant to § 27 of the articles of association of the Company's subsidiary - Ardigen S.A. („Ardigen”) - personal entitlement of Selvita S.A. as to the voting rights attached to series A and B Ardigen preferred shares, whereby each of these series shares gives two votes at the General Meeting of Ardigen, it is conditional upon Mr. Paweł Przewięźlikowski holding at least 33% of the total number of votes in Ryvu - being a company with which was separated in the form of an Organized Part of the Enterprise („OPE”), comprising a separate set of tangible and intangible assets, intended for the implementation of specific economic tasks, under which service activities in the field of biotechnology of the Contract Research Organization type were conducted, including shares in Ardigen S.A., and then OPE was transferred as a result of the corporate split of Selvita S.A. (now Ryvu) to a new company (Selvita CRO S.A.), currently operating under the name of Selvita S.A.

In view of the above, despite the lack of a transaction involving Ardigen shares or changes in the share capital of this company, after the registration of the increase in the share capital of Ryvu, the Company lost the personal voting rights

attached to series A and B preferred shares and currently holds Ardigen shares representing 46.22 % of the total number of votes at the company's general meeting, remaining its largest shareholder.

Prior to the registration of the increase in the share capital of Ryvu, the Company held 54.03% of the total number of votes at the general meeting of Ardigen. The Management Board of the Company emphasizes that the share of Selvita S.A. in the share capital of Ardigen did not change as a result of the registration of the increase in the share capital of Ryvu and amounts to 46.74% of the share capital of Ardigen.

In view of the above, on January 17, 2023 Selvita S.A. ceased to be the parent company of Ardigen within the meaning of Art. 4 § 1 point 4 lit. a) of the Code of Commercial Companies. Thus, the Company no longer has control over Ardigen within the meaning of Art. 5-9 of the International Financial Reporting Standard 10 - Consolidated financial statements (IFRS). Considering that the loss of control occurred only a dozen business days after the end of 2022 and no significant transactions occurred during this period, the Parent Entity ceased to fully consolidate Ardigen's results and other financial data from January 1st, 2023.

Ardigen S.A. is recognized by Selvita S.A. as an associate and the valuation is based on the equity principle.





### 1.3. Impact of Incentive Scheme on 2021-2024 financial results

On May 17, 2021, the General Meeting resolved to adopt a non-diluting Incentive Scheme for 2021-2024 for employees in the form of the right to acquire shares in the Company at a preferential price of 0.19 PLN per share. Mr. Paweł Przewięźlikowski – founder, member of the Supervisory Board and main shareholder of the Company, undertook to transfer to the Company, free of charge, the shares constituting the subject of the program with an order to release them to the company's employees in the total number of 1,247,720. The fair value of the granted shares is determined as at the grant date and recognized over the vesting period in remuneration costs in correspondence with the increase in equity at the time of vesting by employees during the program period. During the reporting period the third tranche of it was distributed.

The valuation of the program, with regards to the shares currently issued to employees as of June 30, 2023, indicated the total estimated cost of PLN 78,021 thousand, which is recognized in the Group's expenses from the second quarter of 2021 to the second quarter of 2026. The impact of the program on the reporting period result is PLN 8,557 thousand and this amount reduces the gross result, net result, EBIT and EBITDA in Q1 and Q2 of 2023 (the details are presented in the table below along with the disclosure of its impact on the balance sheet). The estimated impact on the following years is as follows:

- whole 2023: PLN 11,513 thousand,
- 2024: PLN 3,172 thousand,
- 2025: PLN 902 thousand,
- 2026: 128 thousand.

TABLE 3.

The impact of the valuation of incentive scheme on consolidated statement of comprehensive income in H1 2023 in PLN thousand

Item	From 01.01.2023 to 30.06.2023 including incentive scheme	incentive scheme valuation	From 01.01.2023 to 30.06.2023 excluding incentive scheme
Operating expenses from continuing operations	-171,294		-162,737
EBIT from continuing operations	9,662		18,219
Gross profit from continuing operations	11,087	8,557	19,644
Net profit attributable to the parent entity from continued and discontinued operations	10,321		18,878
EBITDA from continuing operations	31,759		40,316



TABLE 4.

The impact of the valuation of incentive program on consolidated statement of financial position in H1 2023 in PLN thousand

Item	As of 30.06.2023 including incentive scheme	incentive scheme valuation	As of 30.06.2023 excluding incentive scheme
Equity, incl:	269,487	0	269,487
Other reserve capitals	71,101	-8,557	62,544
Net profit attributable to the parent entity from continued and discontinued operations	10,321	8,557	18,878

A detailed description of the program provided in the Note 19 to the interim condensed consolidated financial statements. At the same time, it is important to point out that in the analy-

sis of individual operating segments no impact on the valuation of the incentive scheme was taken due to the one-off and non-cash nature of this event. ●



# 02 — Management Board's comments on financial results

## 2.1. Consolidated data excluding incentive scheme impact

In the first half of 2023, Selvita S.A. Group recognized total operating revenue of PLN 180,956 thousand, which represents 3% increase compared to the corresponding period in 2022, when the total operating revenue amounted to PLN 176,414 thousand. The Group continued growing mainly in segment of services executed in Poland. The operating revenues in Q2 of

the reporting year were impacted by strengthening of Polish zloty and resulted in 3% lower revenues when compared to Q2 of the previous year. The revenues from subsidies of continuing operations increased by PLN 1,058 thousand to PLN 2,779 thousand in the first half of 2023 compared to PLN 1,721 thousand in the corresponding period in 2022.

TABLE 5.

### Selvita S.A. Group – continuing operations

Data in PLN thousand	From 01.01.2023 to 30.06.2023	From 01.01.2022 to 30.06.2022	From 01.04.2023 to 30.06.2023	From 01.04.2022 to 30.06.2022
<b>Revenue</b>	<b>180,965</b>	<b>176,414</b>	<b>89,141</b>	<b>92,354</b>
Segment of Services executed in Poland	107,497	101,095	52,091	53,605
Segment of Services executed in Croatia	72,420	74,911	36,575	38,529
Revenues from subsidies	2,779	1,721	1,615	903
Other operating revenue	48	50	-9	23
Exclusions of revenues between segments	-1,788	-1,363	-1,131	-705
<b>EBIT (excl. incentive scheme)</b>	<b>18,219</b>	<b>34,882</b>	<b>9,540</b>	<b>18,453</b>
%EBIT (excl. incentive scheme)	10%	20%	11%	20%
<b>EBITDA (acc. to IFRS16 excl. incentive scheme)</b>	<b>40,316</b>	<b>52,325</b>	<b>21,218</b>	<b>27,355</b>
%EBITDA (acc. to IFRS16 excl. incentive scheme)	22%	30%	24%	30%
<b>Net profit (excl. incentive scheme) attributable to the Parent Company</b>	<b>18,878</b>	<b>31,219</b>	<b>12,028</b>	<b>15,349</b>
%Net profit (excl. incentive scheme) attributable to the Parent Company	10%	18%	13%	16%
MSSF 16 impact on EBITDA	7,364	6,730	3,711	3,378



**TABLE 6.**  
**Selvita S.A. Group – continuing operations**

Data in PLN thousand	From 01.01.2023 to 30.06.2023	Percentage share	From 01.01.2022 to 30.06.2022	Percentage share
Continuing operations:				
<b>Revenues from external customers</b>	<b>174,566</b>	<b>100%</b>	<b>171,564</b>	<b>100%</b>
Biotechnology companies	94,966	54%	100,228	59%
Pharmaceutical companies	33,872	19%	34,012	20%
Pharmaceutical companies–Big Farma	31,039	18%	24,410	14%
Academia and Foundations	7,848	5%	6,809	4%
Companies operating in the chemical and agrochemical field	6,841	4%	6,105	3%

\* Group considers Big Pharma as global pharmaceutical companies whose revenues in the previous year exceeded \$5 billion.

Due to the decrease in the level of control over Ardigen S.A. (together with Ardigen Inc.) in 2023 as a result of reduction in the number of votes at the general meeting, Selvita S.A. Capital Group did not present the revenues of the Bioinformatics Segment in the sales revenues in the reporting period. As a consequence, the revenues of the Bioinformatics Segment in the first half of 2022 were disclosed as discontinued operations. In the first half of 2023, the Selvita Group recognized only the share in the net profit of Ardigen S.A.

In the first half of 2023, after elimination of the incentive scheme impact, the Group reported EBITDA amounted to PLN 40,316 thousand and decreased by 23% compared to the corresponding period of 2022 which is the result of an increase in operating costs related to the new laboratory space in the Laboratory Services Center in Cracow and the initial stage of its operation (estimated impact of PLN 3.3 million) followed by operating expenses inflation which is gradually passed on to customers and incomplete contracting (utilization rate of human resources was lower by 8 p.p. in the first half of this year compared to the same period last year). As a consequence, EBITDA in the first half of 2023 decreased by 8 p.p. to

22% compared to the same period last year, when it amounted to 30%.

Net profit of Selvita S.A. Group from continuing operations, after adjusting for the impact of the incentive scheme, amounted to PLN 19,308 thousand and is lower by 38% compared to the net profit from continuing operations for the corresponding period of 2022.

The structure of revenues from external customers in the first half of 2023 is mainly focused on biotechnology and pharmaceutical industries and their share in the total of revenues from external customers amounted to 54% and 37% respectively. Compared to the corresponding period of 2022, the share of the revenue mix in biotechnology industry remained at a high level with an increasing share of pharmaceutical companies classified under Big Pharma.



**TABLE 7.**  
Segment of services executed in Poland

Data in PLN thousand	From 01.01.2023 to 30.06.2023	From 01.01.2022 to 31.06.2022	From 01.04.2023 to 30.06.2023	From 01.04.2022 to 30.06.2022
<b>Revenue</b>	<b>110,291</b>	<b>102,822</b>	<b>53,704</b>	<b>54,509</b>
Revenues from external customers	102,147	96,862	48,958	51,193
Between segments and to Ryvu Therapeutics S.A.	5,350	4,233	3,133	2,412
Revenues from subsidiaries	2,779	1,721	1,615	903
Other operating revenue	15	6	-2	1
<b>EBIT (excl. incentive scheme)</b>	<b>10,308</b>	<b>19,804</b>	<b>5,152</b>	<b>10,647</b>
%EBIT (excl. incentive scheme)	9%	19%	10%	20%
<b>EBITDA (acc. to MSSF16) excl. incentive scheme</b>	<b>23,484</b>	<b>28,971</b>	<b>12,440</b>	<b>15,323</b>
%EBITDA (acc. to MSSF16) excl. incentive scheme	21%	28%	23%	28%
IFRS16 impact on EBITDA	3,693	3,006	1,896	1,515

In the first half of 2023 Segment of Services executed in Poland recorded continuing growth of revenues from external customers which increased by 5.5% and amounted to PLN 102,147 thousand compared to PLN 96,862 thousand during the corresponding period in 2022. The very good contracting results in the area of regulatory services reported from the third quarter of 2021 continued in the first half of 2023.

In the first half of 2022 EBITDA ratio was at 21%, which is 7 p.p. lower when compared to the corresponding period of 2022.

Total EBITDA decreased from PLN 28,971 thousand in the first six months of 2022 to PLN 23,484 thousand in the first six months of 2023 mainly as a result of increased operating costs, including the start of operation of the Laboratory Services Centre in Cracow. The estimated total of unused resources related to the Laboratory Services Center in the first half of 2023 amounted to approximately PLN 3.3 million.



**TABLE 8.**  
**Segment of services executed in Croatia**

Data in PLN thousand	From 01.01.2023 to 30.06.2023	From 01.01.2022 to 31.06.2022	From 01.04.2023 to 30.06.2023	From 01.04.2022 to 30.06.2022
<b>Revenue</b>	<b>72,453</b>	<b>74,955</b>	<b>36,568</b>	<b>38,551</b>
Revenues from external customers	72,420	74,911	36,575	38,529
Other operating revenue	33	44	-7	22
<b>EBIT</b>	<b>7,911</b>	<b>15,078</b>	<b>4,389</b>	<b>7,806</b>
%EBIT	11%	20%	12%	20%
<b>EBITDA (acc. to MSSF16)</b>	<b>16,832</b>	<b>23,353</b>	<b>8,779</b>	<b>12,032</b>
%EBITDA (acc. to MSSF16)	23%	31%	24%	31%
IFRS16 impact on EBITDA	3,670	3,725	1,814	1,864

Segment of Services executed in Croatia has been extracted in 2021 as a result of the acquisition of Fidelta d.o.o. (currently Selvita d.o.o.) which is the only legal entity in this operating segment. In the first half of 2023, Selvita d.o.o. continued the level of sales reported in 2022 by achieving sales of PLN 72.453 thousand. In the first half of 2023, the Segment demonstrated its development mainly in the field of ADME / DMPK and in vitro research.

The segment's EBITDA margin in the first half of 2023 amounted to 23%, with the operating profit margin of 11%, which means a decrease compared to the corresponding period of

2022 by approx. 8 p.p. The decrease in profitability was mainly due to the increase in the cost of utilities related to the maintenance of laboratory space and lower contracting in in vivo studies.

Additional information on the operating activities of this segment is provided in section 7 of this report.





TABLE 9.

## Selvita S.A. Group – discontinued operations bioinformatics segment

Data in PLN thousand	From 01.01.2023 to 30.06.2023*	From 01.01.2022 to 31.06.2022*	From 01.04.2023 to 30.06.2023*	From 01.04.2022 to 30.06.2022*
<b>Revenue</b>	<b>25 731</b>	<b>22 618</b>	<b>12 088</b>	<b>11 436</b>
Revenues from external customers	24 897	21 272	12 006	10 848
Revenues from subsidies	817	1 254	78	532
Other operating revenue	17	92	4	56
EBIT	-415	3 233	-347	828
%EBIT	-2%	14%	-3%	7%
EBITDA (acc. to MSSF16)	267	3 879	1	1 163
%EBITDA (acc. to MSSF16)	1%	17%	0%	10%
IFRS16 impact on EBITDA	305	284	159	145
<b>(Loss) / net profit from discontinued operations attributable to the parent company **</b>	<b>-457</b>	<b>1 501</b>	<b>-310</b>	<b>606</b>

\* Supplementary data on discontinued operations not consolidated in the financial statements due to the loss of control over this segment

\*\* included in the consolidated financial statements

Bioinformatics segment (activity discontinued as of December 31, 2022), i.e. Ardigen S.A. (together with Ardigen Inc.) achieved in the first half of 2023 revenues from external customers at the level of PLN 24,897 thousand, which means an increase by 17% compared to the revenues achieved in the previous year, which amounted to PLN 21,272 thousand. In the first half of 2023, this segment incurred an operating loss of PLN 415 thousand compared to the operating profit amount-

ed to PLN 3,233 thousand in the first half of 2022 and resulted from cost inflation not fully passed on to external customers, investments in the development of sales forces (including in the USA) and increased cost of administration related to its adjustment to the scale of operations. The above also resulted in a decrease in EBITDA, which amounted to 1% which decreased by 16 p.p.



## 2.2. Contracted (Backlog)

The value of the 2023 contracts portfolio resulting from commercial contracts and grant agreements as of September 25, 2023 (backlog) amounts to PLN 318,786 thousand and increased by 3% compared to 2023 backlog announced in September last year. The lower backlog dynamics observed for Services provided in Croatia is the result of the more difficult market environment observed since the turn of the year, i.e. access to financing for biotechnology companies in the United States, which makes these companies more cautious in spending their R&D budgets, in particular they conclude FTE cooperation agreements for shorter periods than in the previous year.

In the case of the Bioinformatics Segment, we observe the backlog at a similar level comparable to last year.

Due to the observed deterioration in access to capital by biotechnology companies in the United States, Selvita actively acquired contracts among pharmaceutical clients, including Big Pharma companies in the first half of 2023. The backlog in the area of Big Pharma increased by 31.6% (PLN 13 million) compared to the same period last year.

TABLE 10.  
Backlog \*

Item	For 2023 as of Sep 25, 2023	For 2022 as of Sep 2, 2022	Change	Change %
Services executed in Poland	192,908	178,988	13,920	8%
Services executed in Croatia	121,372	128,066	- 6,694	- 5%
Grants	4,506	2,803	1,703	61%
<b>Total continued operations in the current year</b>	<b>318,786</b>	<b>309,857</b>	<b>8,929</b>	<b>3%</b>
Bioinformatics – external customers	48,367	43,866	4,501	10%
Bioinformatics – grants	853	5,162	- 4,309	-83%
Total Bioinformatics	49,220	49,028	192	0%

\* Backlog includes the revenues already invoiced in a given year

TABELA 11.  
Next year backlog

Item	For 2024 as of Sep 25, 2023	For 2023 as of Sep 30, 2023	Change	Change %
<b>Total continued operations (Commercial Contracts and Grants executed in Poland and Croatia)</b>	<b>62 725</b>	<b>43 888</b>	<b>18 837</b>	<b>43%</b>

The total value of backlog of contracts signed for 2024 amounted to PLN 62,725 thousand and is 43% higher than the contracted volume for 2023 at a comparable moment in 2022. ●

# 03 — The group's assets and the structure of assets and liabilities

## 3.1. Consolidated data

As of June 30, 2023, the total value of the Selvita Group's assets was PLN 572,408 thousand. At the end of June 2023, the most significant current assets are short-term receivables which amounted to PLN 81,745 thousand and cash amounting to PLN 37,353 thousand. The decrease in short-term receivables is mainly the result of decreased tax receivables, subsidies due and a decrease in trade receivables in which Ardigen's receivables are not included at the end of June 2023. The decrease in cash is due to the lack of consolidation of Ardigen's cash, and significant cash flows related to investing activities, servicing financial liabilities that exceed positive cash flows from operating activities.

Fixed assets are mainly Laboratory Services Center, laboratory equipment, recognized assets due to the right to use and deferred tax assets in the amount of PLN 11,330 thousand. The total of non-current assets increased in comparison to December 31, 2022, by PLN 40,414 thousand mainly as a result of increased tangible fixed assets as a result of capital expenditure on the construction of the Laboratory Services Center and recognition of Ardigen as an investment.

TABELA 12.

The assets structure demonstrates the Group's high financial liquidity, which is confirmed by the following ratios:

	30.06.2023	31.12.2022
<b>Current ratio</b> current assets/current liabilities including short-term provisions and deferred revenues (excl. accruals)	1.92	2.06
<b>Quick ratio</b> (current assets-inventory)/current liabilities including short-term provisions and deferred revenues (excl. accruals)	1.82	1.98



The main item in the Selvita Group's equity and liabilities is equity, which amounted to PLN 269,487 thousand as of June 30, 2023. Its slight decrease compared to the end of 2022 is due to net profit generated in H1 2023, recognized increase of reserve capitals from incentive scheme valuation of PLN 8,557 thousand and negative exchange difference from valuation of foreign entities as well as losing control over Ardigen S.A.

Another significant source of financing are long term liabilities which amounted to PLN 208,524 thousand at the end of June 2023. The highest value items in the long-term liabilities are credits and bank loans in total of PLN 117,300 thousand and lease liabilities in total of PLN 65,558 thousand. Short-term liabilities as of June 2023 decreased compared to December 2022 mostly due to lower trade, tax and investment liabilities. ●



## 04 — Current and projected financial condition

The Group's financial position as of the report date is very good. As of June 30, 2023, the value of the Group's cash (including other financial assets) amounted to PLN 39,409 thousand, and at September 24, 2023, the total cash (including other financial assets) of the Selvita S.A. Group amounted to PLN 71,735 thousand. The increase in cash compared to June 30, 2023 is mainly due to the receipt of a tranche of the grant from the National Center for Research and Development resulting from the costs already incurred for the construction and equipping of the Laboratory Services Center in Cracow with laboratory equipment.

The Group meets its obligations timely and maintains sustainable cash levels ensuring its financial liquidity. Cash generated from operations allows to execute the planned investments in the expansion of laboratory infrastructure. ●



# 05 — Significant off-balance sheet items

Significant off-balance sheet items are described in the Note 20 to the mid-year consolidated financial statements. ●

# 06 — Significant events in reporting period

## 6.1. Significant events in reporting period

### Change of consolidation methods of Ardigen S.A. within Selvita S.A. capital group from 2023

Full details of the changes to Ardigen S.A.'s consolidation rules can be found in section 1.1.2 above.

### Real estate acquisition by Selvita d.o.o.

On May 5th, 2023, the Issuer's subsidiary – Selvita d.o.o. with its registered office in Zagreb has concluded with the Municipality of Brdovec ("Seller") an agreement for the acquisition of a property in the town of Savski Marof, with an area of 26,901 m<sup>2</sup> ("Property"). The price for the acquisition of the Property by the Company has been set at EUR 550,000. The acquisition of the Property, located in the immediate vicinity of other companies in the life sciences/pharma sector, aims to secure the possibility of further organic development of the Issuer's Capital Group in Zagreb through the future construction of its own laboratory infrastructure and is consistent with the announced Strategy of the Selvita Capital Group for the years 2022-2025.

### Conclusion of a significant statement of work

On June 29th, 2023 the Company has entered into a Statement of Work with a total value of EUR 1,856,213 under a Framework Agreement entered into on March 21st, 2022 with an early stage drug discovery company with its registered office in Italy.

Under the Statement of Work, the Company will provide FTE-based integrated drug discovery support for a period of 12 months.

## 6.2. Post balance sheet significant events

### Receipt of a significant order by a subsidiary of Selvita S.A.

Issuer's subsidiary, Selvita Services Sp. z o.o. with its registered office in Krakow, received on September 1st, 2023 an order from a biopharmaceutical company based in Europe, the subject of which is to conduct analyses of samples derived from the biologic drug purification process. These analyses serve as essential characterization and validation of activities aimed at confirming that the utilized production process is proper at all stages and will lead to a specific product profile in terms of its quality. Analyses within the scope of the order will be carried out over the course of 8 months. The value of the Order will range from EUR 2,400,368 to EUR 3,600,552 depending on the number of analyses performed.



### Receipt of significant purchase orders from a big pharma company

Selvita d.o.o. has received a number of orders and extensions of existing orders from September 20 to 22, 2023, under a research services agreement concluded on July 16, 2015 between the company and one of the world's largest pharmaceutical companies. The subject of the orders, which will run until July 31, 2024, are integrated ADME/DMPK support services, including physicochemical profiling services, analytical services and in-vivo PK studies to support the client's research programs in the area of drug development. The assignments will be predominantly carried out at the Zagreb laboratory. In addition, the existing cooperation with the client will be expanded to include services in in-vitro and in-vivo pharmacology, which will be completed by the end of 2023.

The total value of the orders is EUR 3,239,630 and CHF 18,486, of which:

- The value of services performed under the orders until the end of 2023 will amount to EUR 1,190,707,
- The value of services performed under orders in 2024 will amount to EUR 2,066,067.

### 6.3. Unusual events occurring in the reporting period

None, except for the event described in section 1.1: Change in consolidation rules of Ardigen S.A.

#### War in Ukraine

Due to the Russian invasion on Ukraine, the Issuer's Management Board has analyzed the potential impact of the ongoing conflict on the Issuer's operations. The Management Board did not identify any significant risks that could affect the Issuer's operations as of the date of this report. In particular, it should be noted that the Issuer does not have any assets in Ukraine, and does not conduct business and operations in Ukraine and Russia. The share of entities from Ukraine, Belarus or Russia as customers and suppliers in the Issuer's structure remains insignificant. Nevertheless, due to risks associated with Russia's actions, including the potential risk of spillover from Russia's current invasion of Ukraine into neighboring countries, and the dynamic and unpredictable nature of the current situation in Ukraine, the Management Board of the Company analyses the Issuer's situation in the context of this geopolitical risk on an ongoing basis. Any new circumstances having a significant impact on the financial results and business situation of the Issuer will be communicated to investors. ●



# 07 — Management board's information on group's activities

## The area of drug discovery

In the second quarter of 2023, activities related to the development of the Integrated drug discovery (IDD) project area continued. In particular, engaging new experienced scientists, including those supporting the team in key markets for the Company such as the United States, who bring significant complementary expertise to the Selvita Group's IDD team. We expect the development of the IDD team to continue in the third quarter as well. The goal is to expand the team to 10 members. In addition, the IDD department was involved in ongoing activity including preparing bids for integrated projects for potential new clients and, securing key extensions and extensions to existing IDD projects for the second half of the year.

In the first half of 2023 the Chemistry Department continued working mainly for the pharmaceutical industry clients on the medicinal chemistry and IDD projects from European, US and UK clients. Selvita's chemistry customer portfolio remains diversified and was additionally expanded to the new one from biotechnology and animal health sector. Selvita scientists across three research sites in Zagreb, Poznan and Cracow have worked on improving the physicochemical properties and activities of new compounds with promising pharmacological profile. One of the main tasks for our medicinal chemists was to design new scaffolds - molecular skeletons around which small libraries of compounds could be built to validate the biological hypothesis of the project to enable the project to move to the next stage of development. Medicinal chemists were responsible for studying the structure-activity relationship (SAR) and designing new, more biologically active compounds using appropriate synthetic strategy.

The team of organic chemists was focusing on the cost-effective and time-efficient syntheses of a series of compound libra-



ries with potential activity against specific molecular targets. The analytical chemists purified and characterized the synthesized substances which were then subjected to further studies including: ADME testing, in vitro pharmacology studies, and PK profile determination. The test results were then fed back to the team of computational and medicinal chemists to enable further iterative structure optimization according to the adopted strategy.

The Computational Chemistry Department continue with growing in first half of the year, to be able support the IDD projects by analysing the data available in the public domain, tracking the SAR for the duration of the projects, by designing next-generation structures using virtual techniques based on the protein



structure, such as virtual screening or focused docking, to identify key ligand-protein interactions. Continuously, Selvita is increasing the range of available modelling tools and put significant emphasis on the application of the artificial intelligence approaches to drug discovery by employing experienced specialists. We expect AI to become an area of dynamic growth within the DD business.

In H1 2023 scientist have been continually involved in two grant projects supported by the National Centre for Research and Development (NCBiR):

1. Creation of ProBiAI platform to produce focused libraries of bioactive compounds by applying machine learning and by integrating the design, parallel synthesis and automatic purification, all of which optimized using artificial intelligence methods in order to accelerate the drug discovery process. The platform will utilize machine learning and it will integrate library design, parallel synthesis, and automatic purification. These processes will be optimized with the help of AI.
2. Technology platform for new generations of drugs against diseases caused by coronaviruses, in particular SARS-CoV-2" - The project is devoted to the establishment of a service platform enabling the discovery of innovative drugs to fight coronavirus infections, particularly COVID-19, based on high throughput screening of the focused library of compounds with potential antiviral properties.

Both platforms were progressing according to the schedule with no major issues to be reported.

In the first half of 2023 the Chemistry Department continued its synthetic work mainly in the area of drug discovery, but also in the area of agrochemistry and optimization of large-scale processes. Department remains very active in implementation and development new synthetic techniques including cold isotope labelling, photochemistry as well as successful campaigns for peptide synthesis projects.

Similarly, to previous years more than 95% of the projects were based on the FTE model.

Selvita's Pharmacology and Translational Research has continued to prosecute IDD projects and integrated pharmacology projects, as well as stand-alone services for its clients during Q2 2023.

Translational team has obtained ethics approvals for collection of lung cancer and breast tumor tissues.

In vitro pharmacology group has continued to support hit and lead identification and optimization on various drug discovery projects, either by in vitro compound testing or ex vivo analysis of animal samples from in vivo studies. A testing of drug candidates, translational research, biomarker exploration and analysis has continued and was performed on collected human tissues for several clients. As a part of novel assay introduction a phenotypisation of primary immunological cells from human tumor tissues was initiated and thermal shift method was introduced for determination of biomarker activity in serum samples

During Q2, most of the work in In vivo Pharmacology and Toxicology was focused on fibrosis, gastro-intestinal diseases, and immuno-inflammation. In addition to compound testing in number of studies across different animal models, a group has implemented a dry powder delivery by Nose-only Exposure System which enables local delivery via inhalation tower, reproducible and fully controllable inhalation compound delivery system in respiratory models.

In collaboration with In vivo Krakow and In vitro Pharmacology departments, the first oncology model was introduced and validated with pharmacological control. During in life phase of the model, primary mice breast tumors and lung metastatic regions were successfully visualized through fluorescence optical imaging via Lago Optical Imager (Spectral Instruments).

Most Q2 activities of In vivo Animal Facility group in Krakow have been focused on completion of infrastructure works in Hexagon building, ordering, installing and validating functionality of delivered equipment, as well as preparing documentation for the accreditation of the facility.

In the first half of 2023 the Department of Cell and Molecular Biology (CMBD) has continued the execution of Drug Discovery projects based on SAR (Structure-Activity Relationship) studies. Scientists (FTEs), which constituted 40% of CMBD employees, have been involved in the execution of above mentioned projects for several foreign biotech and pharma companies from Europe and USA. Their role was to develop and optimize panel of biochemical and cell-based assays that were then used to determine activity and efficacy as well as mechanism of action of novel drug candidates. In H1 In vitro Pharmacology, HTS as well as Biophysical teams acquired several new projects for glo-



bal pharmaceutical companies; a number of currently running integrated projects for US and European clients were extended into H2 2023. Moreover, the In vitro Pharmacology team successfully completed an innovative Drug Discovery project for European client in the area of neuroscience. The novelty lied in the design and synthesis of peptide ligands and designing and executing a screening cascade for assessment of both efficacy and selectivity at the same time.



In H1 High-Throughput Screening team (HTS) acquired several new projects executed for clients from both Europe and USA. The aim of these projects was to analyze libraries of NCEs in order to identify active compounds (hitID, Hit Identification). The team successfully developed, optimised and miniaturized assays for HTS campaign to test a library of over 250k compounds for a large European company. Selvita's Imaging team (HCS) performed several programs for European clients that helped them to understand the mode of action of drug candidates as well as validate the targets (Target Validation). Also the first commercial project utilizing AI in image analysis, performed for a global pharma company, is currently running. It is worth emphasizing that HTS and HCS groups together completed the execution of a screening campaign of 100k compounds for European client.

The In Vitro Pharmacology Team has continued the process of obtaining tumor samples from patients for the analysis of the activity of anticancer compounds. The aim of the project is to build a repository of cell cultures derived from tumors for testing drug candidates (Translational Research in oncology). In order to improve cellular in vitro model quality 3D cultures were introduced in addition to previously used 2D cultures. In parallel a set of immuno-oncology assays was developed by the same team.

Notably, in H1 2023, scientists from Selvita's Cell and Molecular Biology Department have been engaged in the execution of three projects co-financed by National Center for Research and Development (NCBiR). Activities performed within the scope of the first project "HiScAI - Development of phenotypic assay platform, based on high-content screening technology (HCS) with the analysis using artificial intelligence algorithms, to facilitate drug discovery process for treatment of neuroinflammatory and fibrotic diseases" have been focused on development of complex assays enabling multiparametric analysis of phenotypic changes in cells with the use of HCS technology and AI computational procedures. In H1 2023 the HiScAI team worked on automatization of previously developed neuroinflammation-related assays. At the same time a set of assays in the area of fibrosis were successfully developed and optimized and thus an important project milestone was achieved. In Q2 the team started to work on automatization of those assays. The project is executed in collaboration with Ardigen.

In the second project „Technology platform for new generations of drugs against diseases caused by coronaviruses, in particular SARS-CoV-2" CMBD scientists were supporting the activities of chemists by conducting biochemical and cell-based assays on compounds that are supposed to have anti-viral activity. Positive results produced in earlier phase of the project enabled achieving the milestone. The project was continued in H1 2023. In the third project "Creation of ProBiAI platform for generation of targeted libraries of biologically active molecules utilizing machine learning, integrating design, parallel synthesis and automated purification in order to accelerate drug discovery process" biology team completed screening of library internally synthesized by chemistry team, reaching the milestone and enabling proceeding to the last phase of the grant, planned for H2 2023.

In H1 2023 CMBD continued expansion of scientific offer by conducting internal case studies in different drug discovery areas, including immuno-oncology, assay miniaturization, advanced 3D culture models and multiplexed imaging assays. Moreover,



CMBD made investments in new technologies and instrumentation, including high throughput capillary Western Blotting for protein degrader projects and impedance-based label-free cell growth measurement equipment for immune-oncology assays, enabling entirely new assays as well as increasing level of automation and throughput in existing assays.

In H1 of 2023 in addition to revenues generated by medicinal chemistry and integrated projects, a significant part of the Drug Discovery revenues came from the production and purification of recombinant proteins and the structural analysis of protein-ligand complexes, which the Department of Biochemistry special-



izes in. High-quality recombinant proteins have been produced using both bacterial and eukaryotic (insect and mammalian cells) expression systems that enable the production of a wide variety of target recombinant proteins, including those that are relatively difficult to produce and purify. Similarly, crystal-grade proteins have been purified for respective projects and were used to generate high quality diffracting crystals followed by the structure solution and 3D model building to aid in design and validate the prospective therapeutic molecules in the drug discovery process. It should be mentioned the newly introduced research service related to Fragment Based Drug Discovery (FBDD) already resulted in H1 in contracting new projects mainly from the US market. The mentioned research projects were carried out for

both European and US clients representing the global pharmaceutical and biotechnology concerns, as well as smaller biotech companies related to the Drug Discovery activity.

The previous year successfully completed project, which was co-financed by the Małopolska Center of Entrepreneurship significantly expanded the capabilities of the Selvita's Structural Biology Platform related to the crystallography and structural analysis of protein-ligand complexes. It involved the development and implementation of methods for the production and crystallization of various classes of proteins as molecular targets that may be potentially important in the process of drug discovery and in H1 2023 contributed to initiating and advertising a new service, which pertains to Selvita's gallery of the protein "structures of the shelf".

The increased number of projects executed in the Biochemistry Department in H1 2023 was undoubtedly related to the continued recognition of the brand of both services of the Recombinant Protein Production and Structural Biology Platforms as well as implementation of new services such as crystallographic screening of ligand fragments as a part of FBDD service and single particle cryo-EM tomography.

The DMPK business continued with steady growth, reflected by expanded collaborations with existing clients, as well as servicing new Clients.

In H1 2023 the DMPK team collaborated on several integrated drug discovery projects, providing rapid turnaround of in vitro ADME, in vivo PK and bioanalysis, coupled to support with PK/PD and human dose predictions to guide the design of new studies, de-risk frontrunner compounds and assist project teams in decision making.

In Q2/23 we observed a continuous demand in standalone services related to PK/PD and DMPK project consultancies, provided by our experienced teams across sites (Zagreb and Cracow). In addition, the in vitro ADME, in vivo PK, formulation and bioanalytical teams continued to support, as well as grow ongoing screening collaborations, some of which have been extended to the end of 2023. Finally, within DMPK we continue to implement new assays in ADME, develop methods for new biomarkers within bioanalysis, and focus on automation, all aimed at expanding our portfolio and servicing project and Client needs in the future.





## Regulatory studies

In the first half of 2023, the work was focused on three main platforms developed in the laboratory - comprehensive testing of low-molecular active substances and finished products, testing of biological products, and analytical support for clients from the agrochemical industry. In each of these areas, development projects were carried out related to the development and optimization of methods, as well as GxP studies on validation, transfers, and stability and release studies.

In the area of small molecule drugs, the Analytical Laboratory executed projects for one of the largest pharmaceutical companies in the world centered around the development, optimization, and validation of analytical methods for both established and novel products. Furthermore, the same client engaged the laboratory in new undertakings related to stability studies for market-available medicinal products. Continuing collaboration with a key client operating in the field of innovative drugs. The laboratory pursued projects involving ongoing stability studies for a recently introduced low molecular weight product. In addition, work was carried out on the development of methods for new molecules under the support of the Chemistry, Manufacturing, and Controls (CMC) team. For several clients, the methods of analyzing pharmaceutical active substances and preservatives in difficult formulations such as ointments, syrups, and sprays for the oral cavity have been improved. Several new projects concentrated on the analysis of nitrosamines using the LC-MS/MS and GC-MS/MS techniques were effectively executed. Moreover, new contracts involving the identification of impurities were obtained. The company also gained new customers interested in the determination of pyrrolizidine alkaloids in herbal matrices. In the area of the analytical team specializing in gas chromatography analyses in the second quarter of 2023, a significant number of orders for the determination of glycols were recorded. They included the tasks of developing new analytical methods, their validation, and, above all, routine analyses. Moreover, this team has successfully started the first projects aimed at extending services to the area of extractable and leachable substances (E&L) analyses. This is a significant step in the process of the team entering a new area of specialization.

However, in the first half of 2023, the activities of the Department focused primarily on providing services related to biological drugs. During the first half of 2023, the Analytical Laboratory continued to provide specialized services in this area, strictly following the guidelines of the International Conference on Harmonization (ICH). The core expertise focused on in-depth analysis of biopharmaceuticals using a state-of-the-art mass spectrometry (MS) platform and a range of orthogonal analytical methods. This combination created a centralized center for comprehensive support, enabling customers to access a wide range of services seamlessly. In addition, a new analysis system was installed in the laboratory: SEC-HPLC combined with a MALS multi-angle light scattering detector. This connection allows the analysis of the oligomeric state and homogeneity of protein, polymer, and peptide preparations and the determination of their absolute mass.



Due to the effective execution of multidimensional research undertakings in preceding periods, the collaboration with recurring clients within proteomic services centered on qualitative and quantitative analysis of proteins, particularly within intricate matrices, was further strengthened.

In the field of biological products, the laboratory sustained stability studies while also introducing fresh analytical techniques. The package of analytical methods for the new product was also validated. Batch stability studies connected to toxicology assessments were conducted for another biological product. Additionally, an inventive solution was introduced for the same client, involving the assessment of packaging integrity through the utilization of the helium method. The extent of collabora-



tion with a client active in the American market was expanded. This expansion encompassed the initiation of new stability studies, the validation of methods, and the isolation and characterization of impurities. Furthermore, a comprehensive battery of tests related to the characterization of the product, as well as the evaluation of "in use" samples, were executed. Selvita has also reached a significant milestone by inaugurating a partnership with a South Korean company. This agreement revolves around performing analyses to certify batches of biosimilar drug, with the process of transferring analytical methods currently in progress.



During the first half of 2023, the activities of the Biological Assay Laboratory focused on the execution of projects for biological drugs using cell-based, biochemical, and biophysical methods. Many GMP-compliant routine batch release and stability tests have been carried out on biopharmaceuticals of various classes for European, US, and Australian customers. Bioassay validation was completed, and stability studies were started for two peptide vaccines intended to support the therapy of patients suffering from unresectable/metastatic melanoma. Bioassay optimization for testing biological drugs from groups of TNF $\alpha$  inhibitors and ADC (Antibody-Drug Conjugate) was also launched. In addition, the Laboratory has entered into new contracts with customers in Europe and Asia covering the transfer of analytical methods for biological drugs.

In the area of regulatory and release studies, in Quality Control Laboratory, certification of active substances as well as biological and small molecule finished products was carried out for several regular pharmaceutical companies, expanding our portfolio with veterinary drugs. In order to provide complex services to pharmaceutical companies, stability tests of products seasoned under controlled conditions in stability chambers were continued. The transfer of one new product was finished

For agrochemical clients, the activity in the area of physicochemical analysis of formulations and technical materials was expanded by equipping the laboratory with additional devices and increasing the number of projects in this area. In addition to accelerated stability studies, long-term studies have also been launched.



## Ardigen S.A.

In the first half of 2023, Ardigen focused its operations on the promotion and sale of its product and service offer. Following the pandemic, the number of participants at conferences has returned to normal, which is very good news as this is the main channel for acquiring new clients. Ardigen took part in 11 conferences in the US and in Western Europe. The client portfolio expanded by new biotechnology and pharmaceutical companies.

It is worth noticing the effects of operations related to the commercialization of R&D results, which were very intensive in the first half of the year. Sales activities resulted in signing a contract for a pilot project with one of large pharmaceutical companies. The project involves the use of the PhenAID technological platform to predict the action mechanism of small molecule compounds based on the structural data of molecules and their image representation from HCS type experiments. In the second quarter, the pilot project was successfully completed, paving the way for a broader collaboration. A contract was also concluded for the continuation of work with a key partner in the area of Phenotypic drug discovery. The project is focused on the development of algorithms to predict the properties of small molecule compounds based on imaging from HCS experiments.

### Research and development

In the first half of 2023, research and development continued in the area of Immunology extended to biological drugs (Biologics) and in the area of biomedical imaging focusing on machine learning methods supporting the early stage of the small molecule drug discovery process (Small molecules), in particular based on imaging data from phenotypic screening experiments (Phenotypic drug discovery).

As part of operations to increase the recognition and credibility of the developed technologies, two scientific manuscripts (preprints) were published describing the specific application of the technology in the drug discovery process (both papers are currently being reviewed) and another publication on the conducted observational clinical trial was accepted for publication. In addition, one of the developed methods was made public under a free license for academic use.

The team participated in a number of scientific conferences in San Francisco, Boston, Mainz, London and Amsterdam, where they acquired information and established scientific and business contacts.

In the past period, the Phenotypic Drug Discovery team worked in particular on the methods of the so-called virtual screening and hits identification methods (Hit-ID), dedicated to the PhenAID technology platform. The developed methods are based on advanced machine learning methods, in particular deep learning, and are used for multimodal and multi-parameter prediction of the properties of small molecule compounds based on the structural data of the molecules and their image representation from High-Content Screening (HCS) experiments. The proposed methods of virtual screening and Hit-ID are used to select and identify small molecule compounds that are likely to generate the desired phenotypic changes. The results of the research were presented at the SLAS conference in San Diego and SLAS Europe in Brussels. In addition, as part of cooperation in JUMP-CP consortium coordinated by Broad Institute of Harvard and MIT, the Company published a scientific manuscript (preprint) and updated the publicly available application called PhenAID JUMP CP Data Explorer. These operations significantly contributed to extending the recognition and credibility of the offer. ●



# 08 — The capital group structure

## Parent entity

---

Business name	<b>Selvita S.A.</b>
Registered office	ul. Podole 79, 30-348 Krakow
Company (ID)	REGON 383040072
TAX ID (NIP)	6762564595
Legal form	Joint – stock company
KRS Number	0000779822
Website	www.selvita.com

## Affiliates

---

Business name	<b>Selvita Services spółka z ograniczoną odpowiedzialnością</b>
Registered office	ul. Bobrzynskiego 14, 30-348 Krakow
Company ID	(REGON) 122456205
TAX ID (NIP)	676-245-16-49
Legal form	Limited liability company
KRS Number	0000403763
Shareholders	100% of shares held by Selvita S.A.

Business name	<b>Selvita Inc.</b>
Registered office	Boston, MA, USA
Shareholders	100% of shares held by Selvita S.A.
Share capital	1 USD
Establishing date	March 2015

Business name	<b>Selvita Ltd.</b>
Registered office	Cambridge, UK
Shareholders	100% of shares held by Selvita S.A.
Share capital	20.000 GBP
Establishing date	April 2015



## Affiliates

---

Business name	<b>Selvita d.o.o.</b>
Registered office	Prilaz baruna Filipovića 29, HR-10000 Zagreb, Croatia
Shareholders	100% of shares held by Selvita S.A.
Share capital	HRK 51.000.000 / EUR 6.768.863,23

# 09 — Issuer's corporate bodies

## Management Board

---

Bogusław Sieczkowski	President of the Management Board
Miłosz Gruca	Vice President of the Management Board
Mirosława Zydrón	Member of the Management Board
Adrijana Vinter	Member of the Management Board
Dariusz Kurdas	Member of the Management Board
Dawid Radziszewski	Member of the Management Board

## Supervisory Board

---

Piotr Romanowski	Chairman of the Supervisory Board
Tadeusz Wesołowski	Vice Chairman of the Supervisory Board
Paweł Przewięźlikowski	Supervisory Board Member
Rafał Chwast	Supervisory Board Member
Wojciech Chabasiewicz	Supervisory Board Member
Jacek Osowski	Supervisory Board Member

### Audit Committee

Rafał Chwast	Chairman of the Audit Committee
Piotr Romanowski	Audit Committee Member
Tadeusz Wesołowski	Audit Committee Member
Wojciech Chabasiewicz	Audit Committee Member

### Remuneration Committee

Paweł Przewięźlikowski	Chairman of Remuneration Committee
Jacek Osowski	Remuneration Committee Member
Piotr Romanowski	Remuneration Committee Member

During the reporting period there were no changes in Management Board and Supervisory Board. ●



## 10 — Information on the shareholders holding (directly or indirectly) at least 5% of the total number of votes at the general shareholders' meeting of the company and on shares held by members of the issuer's Management Board and Supervisory Board

TABLE 13.

Shares held by members of the issuer's managerial and supervisory bodies as of the date of report publication

Shareholder	Preferred shares*	Other series	No. of shares	% of share capital	No. of votes	% votes at GM
<b>Management Board</b>						
Bogusław Sieczkowski	550 000	392 417	942 417	5,13%	1 492 417	6,83%
Miłosz Gruca	-	60 760	60 760	0,33%	60 760	0,28%
Mirosława Zydróż	-	42 909	42 909	0,23%	42 909	0,20%
Adrijana Vinter	-	12 000	12 000	0,07%	12 000	0,05%
Dawid Radziszewski	-	4 472	4 472	0,02%	4 472	0,02%
Dariusz Kurdas	-	4 286	4 286	0,02%	4 286	0,02%
<b>Supervisory Board</b>						
Paweł Przewięźlikowski	2 932 000	120 663	3 052 663	16,63%	5 984 663	27,41%
Tadeusz Wesołowski (poprzez Augebit FIZ)	-	847 738	847 738	4,62%	847 738	3,88%
Rafał Chwast	-	121 115	121 115	0,66%	121 115	0,55%
Piotr Romanowski	-	100 000	100 000	0,54%	100 000	0,46%
Tadeusz Wesołowski (bezpośrednio)	-	84 975	84 975	0,46%	84 975	0,39%

\*One preferred share gives the right to two votes at the General Meeting of Selvita S.A.



TABLE 14.

## Shares held by members of the issuer's managerial and supervisory bodies

Shareholder	Preferred shares*	Other series	No. of shares	% of share capital	No. of votes	% votes at GM
<b>Management Board</b>						
Bogusław Sieczkowski	550 000	392 417	942 417	5,13%	1 492 417	6,83%
Miłosz Gruca	-	60 760	60 760	0,33%	60 760	0,28%
Mirosława Zydróż	-	42 909	42 909	0,23%	42 909	0,20%
Adrijana Vinter	-	12 000	12 000	0,07%	12 000	0,05%
Dawid Radziszewski	-	4 472	4 472	0,02%	4 472	0,02%
Dariusz Kurdas	-	4 286	4 286	0,02%	4 286	0,02%

<b>Supervisory Board</b>						
Paweł Przewięźlikowski	2 932 000	38 815	2 970 815	16,18%	5 902 815	27,03%
Tadeusz Wesołowski (poprzez Augebit FIZ)	-	847 738	847 738	4,62%	847 738	3,88%
Rafał Chwast	-	121 115	121 115	0,66%	121 115	0,55%
Piotr Romanowski	-	100 000	100 000	0,54%	100 000	0,46%
Tadeusz Wesołowski (bezpośrednio)	-	84 975	84 975	0,46%	84 975	0,39%

\*One preferred share gives the right to two votes at the General Meeting of Selvita S.A.

During the reporting period, Mr. Paweł Przewięźlikowski notified the Company on August 25, 2023 about donating 81848 of Company's shares due to implementation of the Incentive Scheme. Before the donation, Mr. Paweł Przewięźlikowski held 3 052 663


shares, entitling to 5 984 663 votes at the Company's General Shareholder Meeting. After the donation, Mr. Paweł Przewięźlikowski holds 2 970 815 shares, entitling to 5 902 815 votes at the Company's General Shareholder Meeting.



**TABLE 15.**  
Shares held by significant Shareholders of the company as of the date of report publication

Shareholder	Shares	% shares	Votes	% votes
Paweł Przewięźlikowski	3 052 663	16,63%	5 984 663	27,41%
TFI Allianz Polska	2 015 577	10,98%	2 015 577	9,23%
Nationale Nederlanden OFE	1 901 000	10,36%	1 901 000	8,71%
Bogusław Sieczkowski	942 417	5,13%	1 492 417	6,83%
Tadeusz Wesołowski (with Augebit FIZ)	932 713	5,08%	932 713	4,27%

**CHART 1.**  
Shares held by significant Shareholders of the company as of the date of report publication



- Paweł Przewięźlikowski
- TFI Allianz Polska
- Nationale Nederlanden OFE
- Bogusław Sieczkowski
- Tadeusz Wesołowski (with Augebit FIZ)
- Remaining Management Board and Supervisory Board Members
- Remaining Shareholders

# 11 — Additional information

## Proceedings pending at court, before an arbitration institution or a public administration authority

Did not occur.

## Significant non-arm's length transactions with related entities

Did not occur.

## Warranties for loans and borrowings and guarantees granted

Selvita Services sp. z o.o. and Selvita d.o.o. are guarantors of the facility agreement concluded on December 21, 2020 with Bank Polska Kasa Opieki S.A. with its registered office in Warsaw. The facility agreement contains a mechanism of extending the liability for obligations under it to the Issuer's affiliate, in case the Issuer's and Guarantor's share in the consolidated EBITDA of the Selvita Capital Group fell below 75%.

## Other information significant for the assessment of the Issuer's position in the area of human resources, assets, cash flows, financial results and changes thereof and information significant for the assessment of the Issuer's ability to settle its liabilities

Not applicable.

## Factors which, in the Issuer's opinion, will affect the results over at least the following quarter

The results of the upcoming quarters will depend mainly on the following factors:

- Sales dynamics, new customers and extending the current offer
- Access to financing for biotech companies in the US
- Organic growth and subsequent acquisitions
- The level of investment in sales and marketing
- The level of investments in laboratory infrastructure, including in particular equipment
- Changes in currency exchange rates, especially EUR / PLN and USD / PLN - the Company incurs most of the costs in Polish zlotys and generates most of its revenues in foreign currencies

## Description of factors and events, in particular of an unusual nature, having a significant effect on the financial performance

Not applicable.

## Explanations regarding the seasonal or cyclical nature of the Issuer's operations in the reported period

Not applicable.

## Information on inventory write-downs to the net realizable amount and reversal of such write-downs

Not applicable.

## Information on impairment write-downs in respect of financial assets, tangible fixed assets, intangible assets or other assets and the reversal of such write-downs

Information on the changes in impairments is provided in the notes to the consolidated financial statements.

## Information on the set-up, increase, utilization and reversal of provisions

Information on the changes in provisions for holidays and bonuses is provided in note 16 to the consolidated financial statements.

## Information on deferred income tax provisions and assets

Information on deferred income tax provisions and assets is provided in note 6 to the consolidated financial statements.

## Information on significant purchases or disposals of tangible fixed assets

Information on tangible fixed assets is provided in note 7 to the consolidated financial statements.

## Information on significant liabilities in respect of purchases of tangible fixed assets

As at June 30, 2023, the total value of commitments to purchase tangible fixed assets resulting from orders placed



for the purchase of fixed assets amounted to PLN 6,829 thousand.

**Information on significant settlements resulting from court cases**

Not applicable.

**Error corrections relating to previous periods**

Not applicable.

**Information on changes in the economic situation and business conditions, which have a significant effect on the fair value of the entity's financial assets and financial liabilities**

Not applicable.

**Information on the failure to repay a loan or borrowing or a breach of significant terms and conditions of a loan agreement, with respect to which no corrective action had been taken by the end of the reporting period**

Not applicable.

**Informacje o zmianie sposobu (metody) ustalenia wyceny instrumentów finansowych wycenianych w wartości godziwej**

Nie dotyczy.

**Information on changes in the method of valuation of financial instruments measured at the fair value**

Not applicable.

**Information on changes in the classification of financial assets due to a change in their purpose**

Not applicable.

**Information on the issue, redemption and repayment of non-equity and equity securities**

None.

**Information on dividends paid (or declared) in the total amount and per share, divided into ordinary and preference shares**

Not applicable.

**Events that occurred after the date for which the quarterly financial statements were prepared, not disclosed in these financial statements although they may have a significant effect on the Issuer's future financial results**

Not applicable.

**Inne informacje mogące w istotny sposób wpłynąć na ocenę sytuacji majątkowej, finansowej i wyniku finansowego emitenta**

Nie dotyczy.

**Information on changes in contingent liabilities or contingent assets that occurred after the end of the last financial year**

Information on changes in contingent liabilities or contingent assets is provided in note 20 to the consolidated financial statement.

**Other disclosures which may have a material impact on the assessment of the Issuer's financial position and results of operations**

Not applicable.

**Amounts and types of items affecting the assets, liabilities, equity, net profit/ (loss) or cash flows, which are unusual in terms of type, amount or frequency**

Not applicable. ●

# Management Board

Krakow, October 6, 2023

The Management Board of Selvita S.A. confirms that, to the best of its knowledge, the half-year consolidated and standalone financial statements of Selvita Capital Group have been prepared in accordance with the applicable accounting principles and reflect in a true, reliable and clear manner the financial situation of Selvita Capital Group and its financial results.

Report of the Management Board on the activities of Selvita S.A. and Selvita Capital Group contains a true picture of the development and achievements as well as Group's situation, including a description of the basic threats and risks.

.....

**Bogusław Sieczkowski**

PRESIDENT OF THE MANAGEMENT  
BOARD

.....

**Miłosz Gruca**

VICE PRESIDENT OF  
THE MANAGEMENT BOARD

.....

**Mirosława Zydroń**

MEMBER OF THE MANAGEMENT  
BOARD

.....

**Adrijana Vinter**

MEMBER OF THE MANAGEMENT  
BOARD

.....

**Dariusz Kurdas**

MEMBER OF THE MANAGEMENT  
BOARD

.....

**Dawid Radziszewski**

MEMBER OF THE MANAGEMENT  
BOARD





**Selvita S.A.**

ul. Bobrzyńskiego 14  
30-348 Kraków

Uniw. Poznańskiego 10  
61-614 Poznań

**Selvita Ltd.**

CB1 Business Centre  
Nine Hills Road  
Cambridge CB2 1GE

**Selvita Inc.**

East Coast USA  
100 Cambridge St., Suite 1400  
Boston MA 02114

West Coast USA  
611 Gateway Blvd, Suite 120  
South San Francisco, CA 94080

**Selvita d.o.o.**

Prilaz brauna Filipovića 29  
10000 Zagreb

**Ardigen S.A.**

Podole 76  
30-394 Kraków

**Selvita Services Sp. z.o.o.**

Bobrzyńskiego 14  
30-348 Kraków



Your partner of choice in integrated research

investors: [ir@selvita.com](mailto:ir@selvita.com)

media: [media@selvita.com](mailto:media@selvita.com)

[www.selvita.com](http://www.selvita.com)